world-biomarkers-pharma-biotech-2017-posters

2 / 61

Notes:
Volume10, Issue 12 (Suppl) J Proteomics Bioinform, an open access journal
ISSN: 0974-276X
Page 58
conferenceseries.com
World Biomarkers & Pharma Biotech 2017
December 07-09, 2017
December 07-09, 2017 | Madrid, Spain
&
20th International Conference on
PHARMACEUTICAL BIOTECHNOLOGY
9th WORLD BIOMARKERS CONGRESS
JOINT EVENT ON
Anticancer activity of Osmanthus matsumuranus extract by inducing G2/M arrest and apoptosis
Byung Woo Kim, Soojung Jin, You Na Oh, and Hyun Ju Kwon
Dong-Eui University, South Korea
Osmanthus matsumuranus, a species of Oleaceae, is found in East Asia and Southeast Asia. The bioactivities of O.
matsumuranus have not yet been fully understood. Here, we studied on the molecular mechanisms underlying anticancer
effect of ethanol extract of O. matsumuranus (EEOM). EEOM showed the cytotoxic activities in a dose-dependent manner in
various cancer cell lines, but not in normal cells, and HepG2 cells were most susceptible to EEOM-induced cytotoxicity. EEOM
induced G2/M arrest in HepG2 cells associated with decreased expression of cyclin-dependent kinase 1 (CDK1), cyclin A and
cylcin B, and increased expression of phospho-checkpoint kinase 2, p53 and CDK inhibitor p21. Immunofluorescence staining
showed that EEOM-treated HepG2 increased doublet nuclei and condensed actin, resulting in cell rounding. Furthermore,
EEOM-mediated apoptosis was determined by Annexin V staining, chromatin condensation and DNA fragmentation. EEOM
caused upregulation of FAS and Bax, activation of caspase-3, -8, -9, and fragmentation of poly ADP ribose polymerase. These
results suggest that EEOM efficiently inhibits proliferation of HepG2 cells by inducing both G2/M arrest and apoptosis via
intrinsic and extrinsic pathways, and EEOM may be a possible candidate for the anticancer drug development.
Recent Publications:
1. Boutros R, Lobjois V and Ducommun B (2007) CDC25 phosphatases in cancer cells: key player? Good targets? Nat.
Rev. Cancer 7: 495-507.
2. Fulda S and Debatin KM (2006) Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene.
25: 4798-4811.
3. Singh S, Singh P P, Roberts L R and Sanchez W (2014) Chemopreventive strategies in hepatocellular carcinoma. Nat.
Rev. Gastroenterol. Hepatol. 11: 45-54.
4. Stewart Z A, Westfall M D, Pietenpol J A (2003) Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol.
Sci. 24: 139-145.
5. Taylor W R and Stark G R (2001) Regulation of the G2/M transition by p53. Oncogene. 20: 1803-1815.
Biography
Byung Woo Kim has completed his PhD in Pharmacology from Busan University, Busan, Republic of Korea. He is currently working as a Professor at Division of
Applied Bioengineering, Biopharmaceutical Engineering Major, Dong-Eui University and as the Director of Blue-Bio Industry Regional Innovation Center, Dong-Eui
University, Busan, Korea. His research field is Pharmaceutical biotechnology of natural Products.
Byung Woo Kim et al., J Proteomics Bioinform 2017, 10:12(Suppl)
DOI: 10.4172/0974-276X-C1-110